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Combining nanotechnology with glycobiology has triggered an exponential growth of 
research activities in the design of novel functional bionanomaterials (glyconanotechnology). 
More specifically, recent synthetic advances towards the tailored and versatile design of 
glycosylated nanoparticles namely glyconanoparticles, considered as synthetic mimetics 
of natural glycoconjugates, paved the way toward diverse biomedical applications. The 
accessibility of a wide variety of these structured nanosystems, in terms of shapes, sizes, 
and organized around stable nanoparticles have readily contributed to their development 
and applications in nanomedicine. In this context, glycosylated gold-nanoparticles (GNPs), 
glycosylated quantum dots (QDs), fullerenes, single-wall natotubes (SWNTs), and self-
assembled glycononanoparticles using amphiphilic glycopolymers or glycodendrimers have 
received considerable attention to afford powerful imaging, therapeutic, and biodiagnostic 
devices. This review will provide an overview of the most recent syntheses and applications 
of glycodendrimers in glycoscience that have permitted to deepen our understanding 
of multivalent carbohydrate-protein interactions. Together with synthetic breast cancer 
vaccines, inhibitors of bacterial adhesions to host tissues including sensitive detection 
devices, these novel bionanomaterials are finding extensive relevance.
Uniterms: Dendrimer. Glycodendrimer. Vaccine. Bacteria. Nanoparticles. E. coli. 
Lanthanides.
A combinação de nanotecnologia com glicobiologia tem desencadeado o crescimento 
exponencial de atividades de pesquisa em desenvolvimento de novos biomateriais 
funcionais (gliconanotecnologia). Mais especificamente, recentes avanços sintéticos 
para o planejamento sob medida e versátil de nanopartículas glicosiladas, ou seja, 
gliconanopartículas, consideradas como miméticos sintéticos de glicoconjugados naturais, 
prepararam o caminho para diversas aplicações biomédicas. A acessibilidade da grande 
variedade destes nanossistemas estruturados, em termos de forma, tamanho e organização, 
tem prontamente contribuído para seu desenvolvimento e aplicações em nanomedicina. 
Neste contexto, nanopartículas de ouro glicosiladas (do inglês, GNPs), pontos quânticos 
glicosilados (do inglês, QDs), fulerenos, nanotubos de parede simples (do inglês, SWNTs) e 
gliconanopartículas autoconstruídas usando glicopolímeros anfifílicos ou glicodendrímeros 
têm recebido considerável atenção para originar poderosos instrumentos de imagem, 
terapêutico e de biodiagnóstico. Esta revisão fornecerá a visão global das mais recentes 
sínteses e aplicações de glicodendrímeros em glicociência que têm permitindo aprofundar 
nosso conhecimento das interações multivalentes proteína-carboidrato. Estes novos 
biomateriais estão sendo considerados de grande relevância, junto com vacinas sintéticas 
de câncer de mama, inibidores de adesão bacteriana em tecidos hospedeiros incluindo 
instrumentos de detecção sensível. 
Unitermos: Dendrímeros. Glicodendrímeros. Vacina. Bactéria. Nanopartícula. E.coli. 
Lantanídeos.
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INTRODUCTION
Nanometric glycoconjugates
Biologically relevant sugar residues, linked to 
dendritic scaffolds and Nanoparticles (NPs), are becom-
ing widely used as multivalent carbohydrate platforms 
toward biomedical applications. The globular shapes and 
nanometer sizes of NPs constitute efficient multivalent 
glycomimetics possessing greatly improved binding 
properties to their cognate protein receptors. In addition, 
different therapeutic molecules covalently bound to a 
single nanoparticle provide hybrid glyconanoparticles 
useful as biosensors, drug targeting devices, and imaging 
(Wang et al., 2010). Moreover, the stability, cytotoxicity 
and electronic, optical, and magnetic properties of NPs 
can be readily fine tuned. The sizes and shapes of NPs 
were shown to take part in several vital functions in their 
in vivo characteristics. For instance, liver, renal clearance, 
and mononuclear phagocyte uptake constitute just a few 
examples wherein the advantages of NPs could be tar-
geted. Intracellular delivery is predominantly effected by 
the NPs charges together with surface groups specialized 
toward cellular receptors necessary for cells’ nutrition or 
simply by one of the endocytic mechanism. Additionally, 
surface groups functionalization also play major factor 
toward stability, toxicity and long-term circulation of NPs. 
Poly(ethylene glycol) and carbohydrates including mono 
and polysaccharides are often used to reduce the toxicity 
and to improve the long-term blood circulation of NPs.
For chemotherapy, drugs NPs conjugates have the 
additional intrinsic ability of being more readily accumu-
lated in tumor tissues due to the enhanced permeability 
and retention (EPR) effect of the tumor vasculature. The 
increased vascular permeability of NPs by the tumor blood 
vessels and ineffective lymphatic drainage can lead to NPs 
accumulation in the tumor. As such, nanoparticles conju-
gated to carbohydrates could be effective chemotherapeu-
tic agents against cancers and viral/bacterial infections that 
use host glycans as adhesion principles. This subject will 
be extensively examined throughout this review.
The combination of glycobiology and nanotechnolo-
gy has triggered a rapid growth of research activities in the 
design of novel functional bionanomaterials (glyconano-
technology). More specifically, recent synthetic advances 
towards the tailored design of glyconanoparticles, paved 
the way toward diverse biomedical applications. The 
accessibility of a wide variety of these structured nano-
systems, in terms of shapes, sizes, and organized around 
stable nanoparticles have readily contributed to their 
development and applications in nanomedicine (Doane, 
Burda, 2012; Kottari et al., 2013). In this context, glyco-
sylated gold-nanoparticles (GNPs), glycosylated quantum 
dots (QDs), fullerenes, single-wall natotubes (SWNTs), 
and self-assembled glyconanoparticles using amphiphilic 
glycopolymers or glycodendrimers have received consid-
erable attention to afford powerful imaging, therapeutic, 
and biodiagnostic devices (Figure 1).
This review will provide an overview of the most 
recent syntheses and applications of glyconanoparticles 
FIGURE 1- Schematic representation of accessible multivalent glyconanoparticles reviewed in this chapter.
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FIGURE 2- Left: Overview of applications involving glyconanoparticles. Right: Cell surface carbohydrates are involved in several 
pathogenicities including cancer and bacterial adhesions. Adapted from: http://www.glycotech.com (formerly BioCarb Chemicals).
in glycoscience that have permitted to deepen our under-
standing of multivalent carbohydrate-protein interactions. 
A particular emphasis will be directed to cancer vaccines 
together with inhibitors of bacterial adhesions of uropatho-
genic E. coli to host tissues. Figure 2 (left) illustrates the 
many different fields into which glyconanoparticles have 
began to play major roles that span from drug delivery, 
imaging, nanomaterial sciences, and biosensors, besides 
the two applications discussed below (De La Fuente, 
Penadés, 2006; Cipolla, Peri, Airoldi, 2008; Garcia, Mar-
radi, Penadés, 2010; Narrain, 2011; Garcia et al., 2011; 
El-Boubbou, Huang, 2011; Marradi et al., 2013 ). This 
review will also briefly described our ongoing activities 
in the area of sugar-based gold nanoparticles and up con-
verting lanthanide NPs. The physiological roles played 
by cell surface carbohydrates are several folds. As seen in 
Figure 2 (right), glycans can be responsible for cell cell 
interactions, pathogenic infections, cancer cell prolifera-
tion and metastasis. Several of these carbohydrate-based 
recognition phenomena may also lead to apoptosis. The 
interactions are highly dependent on the sugar densities 
and multivalency has been frequently evoked to rationalize 
the detrimental pathophysiological outcome.
Tumor associated carbohydrate antigens
Carbohydrates are T-cell independent antigens 
since they are incompetent to trigger the participation 
of T-helper cells (Danishefsky, Allen, 2000; Roy, 2004; 
Becker et al., 2006; Liakatos, Kunz, 2007; Roy, 2008; 
Wilson et al., 2008; Guo, Boons, 2009; Guo, Wang, 
2009; Westerlind, Kunz, 2011; Morelli, Poletti, Lay, 
2011; Galan, Benito-Alifonso, Watt, 2011; Roy, Shiao, 
2011). Consequently, they cannot induce immune cell 
proliferation, antibody class switch and affinity/specific-
ity maturation on their own, as opposed to peptides and 
proteins that are T-cell dependent antigens. Paradoxi-
cally, the major successful developments achieved with 
carbohydrate-based vaccines stem from the fact that, 
when properly conjugated to protein carriers, bacterial 
capsular polysaccharides (CPS) became capable of ac-
quiring the requisite immunochemical ability. The four 
known carbohydrate antigen uptake mechanisms by 
antigen presenting cells (APCs) are well documented 
(Cobb, Kasper, 2005; Icart et al., 2008). The key to suc-
cessful vaccines resulted from the fact that the common 
protein carriers contained at least one ~15-amino acids 
sequence (T cell epitopes) known to bind strongly to 
Major Histocompatibility Complex (MHC). Because 
B-cells possess surface immunoglobulins (Igs) that bind 
to multivalent carbohydrate antigens such as polymers 
and polysaccharides, it was anticipated that glycoden-
drimers (Chabre, Roy, 2009; Chabre, Roy, 2010) could 
also bind to these Igs and trigger signaling events leading 
to the production of low affinity and low specificity IgM 
antibodies. Moreover, some APCs express mannopy-
ranoside binding receptors (lectins) known as DC-SIGN 
(Dendritic Cell-Specific Intercellular adhesion molecule-
3-Grabbing Non-integrin) also known as CD209 (Cluster 
of Differentiation 209) (Figdor, Van Kooyk, Adema, 
2002). DC-SIGN on macrophages and dendritic cells 
recognizes and binds to mannose type carbohydrates, a 
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class of pathogen associated pattern recognition recep-
tors (PRRs) commonly found on viruses, bacteria and 
fungi. These binding interactions activate endocytosis 
and phagocytosis. Consequently, mannoside-bearing 
glycodendrimers are becoming “cargo molecules” to 
deliver other antigens (Chabre, Roy, 2012).
The other APCs uptake mechanisms are based on 
Toll-like receptors (TLRs) (Spohn et al., 2004). Known 
human Toll-like receptors constitute a family of ten pro-
tein members recognizing a wide variety of microbial 
lipophilic molecules (Park et al., 2009). One of which 
has particularly retained the attention of glycochemists, 
the TLR2 receptor (Kang et al., 2009). Another entry 
mechanism was also recently identified wherein zwit-
terionic polysaccharides (ZPS) could invoke, on their 
own, MHC class II-mediated CD4+ T-cell responses in the 
absence of protein carriers (Avci, Kasper, 2010). Hence, 
recent reports are now emerging describing the covalent 
attachment of carbohydrate epitopes to such carriers, in-
cluding one of the tumor associated carbohydrate antigen 
presented herein (De Silva et al., 2009). In this review, 
a description of various “glycodendrimers” (in a wide 
sense) constructs will be described concentrating on the 
most actively pursued vaccine candidates against tumor 
associated carbohydrate antigens (TACAs).
GLYCODENDRIMER VACCINES
The glycoproteins and glycolipids of the outer 
cell membranes of cancer cells over express particular 
O-glycans (Ragupathi, 1996; Hakomori, 2001). The 
glycoproteins constitute a family of proteins collectively 
known as mucins (MUC) with MUC1 representing the 
most widely investigated (Springer, 1984). These glyco-
proteins are heavily glycosylated on normal cells while 
limited O-glycosylations on cancer cells have been clearly 
demonstrated (Figure 3). Gangliosides (GM2, GD2, GD3) 
and neutral glycolipids (globo-H and Lewisy) on epithelial 
tumor cells of breast, lung, colon, bladder, and prostate 
are also considerably altered both in number and in struc-
tures (Livingston, 1995; Roy, 2004; Freire et al., 2006; 
Franco, 2008; Roy, 2008; Roy, Shiao, 2011). In the tumor-
associated carbohydrate antigens (TACAs) of mucins, a 
down-regulation of a key glycosyltransferase triggers the 
accumulation of shorter glycans, the most common being 
the TN- and the TF-antigens (TF = Thomsen-Friedenreich), 
respectively. In healthy tissues, the active glycosyltrans-
ferase enzymes are responsible for a much more complex 
pattern of glycosylation (Figure 4). The consequence of 
these altered glycosylation profiles results in the over 
accumulation of TACAs which are otherwise cryptic 
(masked) on healthy tissues. MUC1 is a membrane-bound 
mucin and is found in more than 90% of breast carcinomas 
(Hattrup, Gendler, 2008). Consequently, most efforts to 
provide classical carbohydrate-based vaccines have been 
devoted to the above antigens and the related ones (Figure 
3) (Ragupathi, 1996; Livingston, Ragupathi, 1997; Finn, 
2003; Bast Jr et al., 2005).
Hence, the immediate target in prophylactic vaccine 
preparations was to trigger humoral immunity, i.e. stimula-
tion of long lasting, high affinity antibodies, preferably of 
the IgG isotypes against the carbohydrate antigens. Sev-
eral groups have developed systematic research projects 
aimed at the synthesis of various vaccine compositions 
(Livingston, 1995; Danishefsky, Allen, 2000; Kudryas-
hov et al., 2001; Roy, 2004; Spohn et al., 2004; Freire 
et al., 2006; Liakatos, Kunz, 2007;Roy, 2008; Franco, 
2008; Guo, Wang, 2009; Roy, Shiao, 2011). In spite of 
the limited success encountered with traditional vaccine 
formulations based on vaccine carriers harboring the 
FIGURE 3 - Typical structures of representative TACAs from glycoproteins (blue) and glycolipids accumulated on cancer cells.
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FIGURE 4 – Carbohydrate structures of mammalian cell surface mucins in healthy and cancer cells. Glycosylation patterns are 
much more elaborated in healthy mucins, thus masking key tumor associated carbohydrate antigens that become heavily exposed 
in tumors.
above carbohydrate antigens (Koganty, Yalamati, Jiang, 
2008), considerable efforts have been recently devoted to 
the chemical design of glycodendrimers. These facets are 
further contributing to the need of well defined chemical 
constructs (Kaiser et al., 2010).
Syntheses of vaccines, screening antigens, and 
glycodendrimers
Mouse monoclonal antibodies (MAb) against the 
TF-Ag (2) to be used in evaluating the relative affin-
ity of glycodendrimers were generated using a protein 
conjugate (17) (Rittenhouse-Diakun et al., 1998; Baek, 
Roy, 2000; Donovan et al., 2000; Baek, Roy, 2001a,b; 
Baek, Rittenhouse-Olson, Roy, 2001; Roy, Baek, 
Rittenhouse-Olson, 2001; Baek, Roy, 2002a,b). The 
vaccine was prepared from an N-acrylamido deriva-
tive (11) of an amino-ending TF intermediate derived 
from 9 (Baek, Rittenhouse-Olson, Roy, 2001) using 
1,4-conjugate addition from the ε-amino groups of the 
lysine residues of either bovine serum albumin (BSA) 
or the more immunogenic tetanus toxoid (TT) (Figure 
5) (Rittenhouse-Diakun et al., 1998). A glycopolymer 
was also prepared to screen the above MAb and to serve 
as model cell surface mucin for solid-phase competitive 
immunoassays (Baek, Roy, 2000; Donovan et al., 2000; 
Baek, Roy, 2001a;). In this way, two monoclonal anti-
bodies were selected for binding specificity and affinity 
studies. One was an IgM, while the selected IgG was of 
the IgG3 subfamily (JAA-F11) (Rittenhouse-Diakun et 
al., 1998). Dendritic scaffolds made of poly(amidoamine) 
(PAMAM (12)) (Figure 5), poly(propylene imine), 
N,N-bis(acrylamidoacetic acid) (not shown), and finally 
hyperbranched L-lysine were used to construct relatively 
small glycodendrimers bearing TF-antigen moieties (18, 
19) (Baek, Roy, 2002a,b). Few glycodendrimers were 
also linked to fluorescein and biotin probes to generate 
ligand 20 that can be used to detect TF-Ag receptor sites 
(Figure 6).
With these tools in hand, the required Glyco-
PAMAM dendrimers bearing the TF-Ag (13-16) were 
next prepared by amide bond formation between TF-Ag 
acid (10) and PAMAM dendritic cores (12) to generate 
G0 to G3 (n = 4 to 32) glycodendrimers (13-16) (Figure 5) 
(Baek, Rittenhouse-Olson, Roy, 2001; Baek, Roy, 
2002a,b;). Analogously, several other TF-glycodendrimers 
were constructed, including those built on hyperbranched 
L-Lysine (18, 19) (Figure 6) (Baek, Roy, 2001b).
The relative potencies of the TF-glycodendrimer 
families (13-16) to inhibit the binding of mouse monoclo-
nal IgG antibody to ELISA plate coated TF-copolymer was 
determined using goat anti-mouse monoclonal IgG and 
the results are shown in Table I. For the glycoPAMAMs, 
the degree of inhibition was proportional to the conjugate 
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valencies which showed maximum inhibition whith the 
32-mer 16 (G3). The concentrations of TF-PAMAMs 
to give 50% inhibition (IC50) of the antibody-binding to 
the coated TF-copolymer were 5.0, 2.4, 1.4, and 0.6 nM 
FIGURE 5 - Representative TF-vaccine and glycodendrimers built around PAMAM scaffolds (Baek, Roy, 2002a; Baek, Roy, 
2002b). Red inset: Structure of the G3 poly(amidoamine) glycodendrimer after covalent incorporation of p-isothiocyanatophenyl-
β-D-lactoside into the peripheral sphere of the starburst PAMAM dendrimer (32-mer) (see section below).
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for conjugates G0-G3 (13-16), respectively where the 
monomeric TF-Ag (9) required 2.3 µΜ. These values 
represent 460-, 960-, 1700- and 3800-folds enhancement 
of inhibitory potencies over that of the TF-monomer. By 
comparison to the N,N-bis(acrylamidoacetic acid)-based 
dendrimer series (not shown) (Roy, Baek, Rittenhouse-
Olson, 2001), the dimer showed the poorest inhibitory 
value (IC50 174 nM), while the two homologous tetramers 
were approximately equipotent with IC50 of 18 nM and the 
corresponding hexamer showed a noticeable decrease in 
affinity with IC50 value at 48 nM. For that series and on a 
per TF-Ag basis, the tetramers were the most potent with 
~31-fold enhancement over that of the monomer. When 
compared together, the glycoPAMAM series G0-G3 
(n = 4-32) (13-16, Figure 5) showed the best value with 
overall 3.7-fold better binding ability over the N,N’-
bis(acrylamidoacetic acid)-based dendrimer series. The 
explanation for these observations is not straightforward 
but could partly be due to a slightly longer distance be-
tween the aglyconic oxygen and the branching fifteen 
atoms for PAMAMs in comparison to the nine atom linkers 
of the later, which may provide better accessibility of the 
TF-Ag for the receptor sites within the antibody combining 
sites. Interestingly, these results confirmed earlier findings 
(Roy, Baek, Rittenhouse-Olson, 2001) illustrating that 
tetrameric TF-Ag clusters may represent the optimum 
size for an antibody-glycocluster inhibition. The protein 
binding properties of these glycodendrimers were also 
evaluated using the plant lectin from Arachis hypogaea 
(peanut lectin) which constitutes a perfect antibody mimic, 
albeit tetravalent (Baek, Roy, 2002b).
It is also worth mentioning that while these TF-
dendrimers were highly antigenic, that is, they could 
TABLE I - Relative inhibitory potencies (IC50′s) of various TF-antigen dendrimers to mouse monoclonal antibody (IgG3) binding 
to coated TF-copolymer
Compound IC50 (nM)a Relative potencya
Monomer 2300 1
13 PAMAM (G0) (4-mer) 5.0 (20.0) 460 (115)
14 PAMAM (G1) (8-mer) 2.4 (19.2) 960 (120)
15 PAMAM (G2) (16-mer) 1.4 (22.4) 1700 (106)
16 PAMAM (G3) (32-mer) 0.6 (19.2) 3800 (119)
dimerb 174 (347) 13.3 (6.6)
4-merb 19 (76) 120.5 (30.1)
4-merb 18 (72) 128.1 (32.2)
6-merb 48 (288) 47.8 (8.0) 
a Values in parentheses are based on per TF-antigen basis. bN,N’-bis(acrylamidoacetic acid)-based dendrimer series (not shown) 
(Baek, Rittenhouse-Olson, Roy, 2001).
strongly bind to antibodies, they all failed to illicit any 
immune response hence, they were shown to be non-
immunogenic (Toyokuni, Singhal, 1995). In other words, 
potent synthetic carbohydrate antigens may represent poor 
immunogens. The lack of immunogenicity was also con-
firmed when hyperbranched L-lysine were used as scaf-
folding dendrimers (18, 19) (Figure 6) (Baek, Roy, 2001b). 
These observations can now be readily rationalized on the 
basis that, even when TACAs are presented as multivalent 
entities, they lack immunocompetent molecular entities 
(pattern recognition receptor ligands, as described above.
Another noteworthy applications was found with 
a TF-linked poly-L-Lysine tetrameric dendron (18) onto 
which was anchored a biotin probe to provide 20 (Figure 
6). Dendron 20 was found very useful in enzyme linked 
immunosorbent assays (ELISA) as it could be anchored 
to solid-phase through streptavidin binding for antibody 
capture (Baek, Roy, 2001b; Baek, Roy, 2002a) (Figure 
7). Curiously and despite their apparent hydrophilicity, 
the TF-PAMAM dendrimers were also capable to directly 
coat the surface of hydrophobic ELISA plates (Baek, Roy, 
2002b). 
However, when conjugated to effective immunogen-
ic protein carriers, the TF-antigen together with its shorter 
TN-antigen (α-GalNAc-O-Ser/Thr) precursor as well as 
their sialylated counterparts (see Figure 3) were strongly 
immunogenic (Toyokuni et al., 1994). For instance, natural 
asialoovine submaxillary mucin (A-OSM), known to con-
tain almost exclusively TN antigens, provided protection 
against challenge with a highly invasive mouse mammary 
carcinoma. The vaccine also induced in vitro proliferation 
of CD4+ T lymphocytes, thus indicating cellular immunity 
and protection. In addition, recent findings also suggested 
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FIGURE 6 - Glycodendrimers built by solid-phase peptide synthesis using L-lysine as A2B monomer (both α- and ε-amino groups 
are used simultaneously). The acid terminal, obtained from the Wang resin, was then coupled to a biotin hydrazide probe by amide 
coupling.
that a linear trimeric version of the TN-antigen was more 
antigenic. Thus, analogous artificial vaccines composed 
of mono-, di- and- tri-meric TN-antigens coupled to Ovine 
Serum Albumin (OSA), successfully provided antibody 
responses; although the trimeric antigen was more potent. 
2nd Generation TF-vaccine
As mentioned, the Thomsen-Friedenreich TF-
antigen over expression on the cell surface of several 
types of tumor cells, contributes to cancer cell adhesion 
and severe metastasis to sites containing TF-Ag binding 
lectins (lungs, liver, lymph nodes). Our group showed 
that a highly specific immunoglobulin IgG3 monoclonal 
antibody (MAb) developed against the TF-Ag (JAA-F11) 
(Rittenhouse-Diakun et al., 1998) impeded TF-Ag binding 
to vascular endothelium, blocking a primary metastatic 
step and providing a survival advantage (Heimburg et al., 
2006). In addition, in patients, even low levels of antibod-
ies to TF-Ag seem to improve prognosis; thus, it is ex-
pected that vaccines generating antibodies toward TF-Ag 
would be clinically valuable. Unfortunately, vaccinations 
with protein conjugates of TACAs have induced clinically 
inadequate humoral immune responses. 
Consequently, we tested the hypothesis that vacci-
nations with unique TF-Ag peptide mimics may generate 
more favorable immune responses to TF-carbohydrate 
epitopes on tumor cells, useful for active immunotherapy 
against relevant cancers. Peptide mimics of TF-Ag were 
thus selected by phage display biopanning (Figure 8) 
using JAA-F11 and rabbit anti-TF-Ag Ab and were 
analyzed in vitro to confirm TF-Ag peptide mimicry. 
Biopanning with mouse monoclonal Ab and rabbit Ab 
eluted with TF-Ag decreased the likelihood of nonspe-
cific binding to Ab. The percent recovery of binding 
phage increased with each round of biopanning. Final 
phage amplification and selection were performed with 
immunoprobing of titered phage followed by positive 
phage amplifications. Amplification of isolated phage 
was needed to obtain a sufficient amount of phage for 
subsequent experiments.
To identify the peptides that were able to mimic TF-
Ag in immunoblot analysis and inhibition ELISA experi-
ments, the selected phage were sequenced. Three phage 
clones returned the same sequence, providing evidence of 
a good mimicking sequence, and additional four different 
sequences were obtained. Two sequences of higher affini-
ties are illustrated in Figure 9 and the phage that reacted 
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best in the immunoblots and inhibition ELISAs using our 
IgG3 antibody (JAA-F11) and rabbit anti–TF-Ab was ana-
lyzed in vitro to further confirm TF-Ag peptide mimicry 
(Heimburg-Molinaro et al., 2009). Although both peptides 
21 and 22 showed good affinity, fifteen-mer peptide mimic 
(21) (Figure 7) of the TF-Ag (H-I-H-G-W-K-S-P-L-S-S-L-
G-G-G) was initially chosen as the focus of further studies 
and chosen for dendrimer formation.
In vitro, TF-Ag peptide mimics bound to TF-Ag–
specific peanut agglutinin and blocked TF-Ag–mediated 
rolling and stable adhesion of cancer cells to vascular 
endothelium. In vivo, the immunization with TF-Ag–
mimicking multiple antigenic peptides induced TF-Ag 
reactive Ab production. This novel active immunotherapy 
approach will hopefully decrease tumor burden in cancer 
patients by specifically targeting TF-Ag positive cancer 
cells and blocking metastasis. This represented, to the best 
of our knowledge, the first case of a dendritic peptidomi-
metics of a carbohydrate related antigen.
Other related TF-antigen vaccines
Another valuable alternative of the TF-antigen in-
volving glycodendrimers with requisite immunochemical 
abilities has been recently disclosed (Shiao, Roy, 2012; 
Pri, 2013). Cumulated investigations pointed to the op-
timum structural requirements to construct successful 
glycoconjugate vaccines for cancer immunotherapy: 1) 
the presence of key TACAs as recognition motif and act-
ing as B-cell epitope against which antibodies should be 
raised; 2) the presence of CD4+ Th cell peptide epitope 
and CD8+ T lymphocyte (CTL) to trigger both humoral 
and cytotoxic immunity, respectively; 3) the incorpora-
tion of non-immunogenic and non-toxic lipidic adjuvant 
FIGURE 7 – Panel A: EIA using TF-Ag L-lysine tetramer () and biotin labeled T-Ag tetramer () versus indirect mouse IgG 
capture by streptavidin coating. Peroxidase –labeled goat anti-mouse IgG and ABTS-H2O2 were used for detection. Panel B: 
EIA showing the coating properties of PAMAM-based T-Ag dendrimers (13-16) towards mouse IgG. Dendrimers: dimer (), 
tetramer (▲), 16-mer (), and 32-mer (). Peroxidase-labeled goat anti-mouse IgG and ABTS-H2O2 were used for detection.
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targeting the Toll-like receptors 2 (TLR-2) to provide 
self-adjuvanting property of the construct (Bettahi et 
al., 2009); and 4) the multivalency, either insured by the 
multi-task platform used to expose one or several different 
epitopes, or naturally generated through the propensity of 
lipid derivatives to form liposomes.
Dumy et al. capitalized on these cumulated obser-
vations toward the achievement of a fully synthetic four-
component antitumoral vaccine (24, Figure 10), built on a 
non-immunogenic cyclodecapeptide template (known as 
“RAFT” for “Regioselectively Addressable Functional-
ized Templates) (Dumy et al., 1995; Renaudet et al., 2008; 
Renaudet et al., 2010; Fiore et al., 2013). The optimized 
multiepitopic construct incorporated four copies of a TN 
antigen analogue as B cell epitope, the universal CD4+ 
helper T-cell peptide from the type I-poliovirus protein 
together with a CD8+ CTL from ovalbumin (OVA257-264 
peptide SIINFEKL) to which was covalently added pal-
mitic acid as lipid adjuvant. The peptidic epitopes were 
further combined to the scaffold through disulfide bridge 
to afford the desired vaccine nanoparticles composed of 
ovalbumin glyco-lipopeptide (OVA-GLP) 4 (Figure 10) 
(Bossu et al., 2011).
The study highlighted both B- and T-cells anti-
genicity as well as immunogenicity in vitro and in vivo 
assays. The authors first assessed the safety, the im-
munogenicity and the protective efficacy of 24 using 
MO5/BALB/c tumor mouse model. The investigations 
revealed the production of the tumor-specific antibodies 
(Abs) developed against the TN cluster displayed in the 
synthetic vaccine that efficiently recognized the native 
form of TN antigen presented on human tumor cells, as 
determined by flow cytometry between the immune se-
rum IgG and the common breast cancer cell line MCF7. 
The efficient stimulation of T-cells was also observed, 
together with tumor regression and significant increase 
of survival in mice inoculated with MO5 carcinoma cells 
in both immunotherapeutic and immunoprophylactic set-
tings. These promising results thus suggest that RAFT 
scaffold provides suitable tools for engineering other 
potent synthetic anticancer vaccines with optimized 
structural variations.
FIGURE 8 – Generation of phage display library used in biopanning and selection against two TF-Ag binding antibodies. 
Amplification and dendrimerization afforded a peptide vaccine that mimicked the carbohydrate epitope.
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FIGURE 9 - Antigenic carbohydrate epitopes can be functionally replaced by peptide sequences. When multimerized into a dendritic 
molecular architecture, the resulting neoglycoconjugates can not only be recognized by anti-carbohydrate antibodies but can also 
act to trigger a successful immune response.
Glycodendrimers as potential antimetastatic agents
Several studies have demonstrated that interactions 
mediated by the cancer-associated Thomsen-Friedenreich 
glycoantigen (TF-Ag) and the carbohydrate-binding protein 
galectin-3 play an important role in several rate-limiting 
steps of cancer metastasis. An important finding (Glinsky 
et al., 1996; Almogren et al., 2012; Glinskii et al., 2012) 
demonstrated the ability of a synthetic small-molecular-
weight nontoxic carbohydrate-based TF-Ag mimic lactu-
lose-L-leucine (Lac-L-Leu) (Glinsky et al., 1996) to inhibit 
metastasis in vitro and, ultimately, prostate cancer bone 
metastasis in vivo. Using an in vivo mouse model, based on 
intracardiac injection of human PC-3 prostate carcinoma 
cells stably expressing luciferase, the authors investigated 
the ability of Lac-L-Leu to impede the establishment and 
growth of bone metastasis. A number of assays were used 
to assess the effects of Lac-L-Leu on tumor cell adhesion 
to the endothelium. They reported that daily intraperito-
neal administration of Lac-L-Leu resulted in a three-fold 
decrease in metastatic tumor burden compared with un-
treated control. Mechanistically, the effect of Lac-L-Leu, 
which binds and inhibits galectins by mimicking essential 
structural features of the TF-Ag, was associated with a 
dose-dependent inhibition of prostate cancer cell adhesion 
to bone marrow endothelium. They concluded that small 
molecular-weight carbohydrate-based compounds targeting 
β-galactoside–mediated interactions could provide valuable 
means for controlling and preventing metastatic prostate 
cancer spread to the skeleton.
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Importantly, a few chemistry teams are actively in-
volved in the search for potent galectin inhibitors (André 
et al., 1999; Giguère et al., 2006; Sirois, Giguère, Roy, 
2006a; Giguère et al., 2006b; Giguère et al., 2008; André 
et al., 2010; Öberg, Leffler, Nilsson, 2011; Giguère et 
al., 2011; St-Pierre et al., 2012). Moreover, both small 
drug-like molecules 29-32 (Figure 11) together with gly-
codendrimers (Figure 5) (André et al., 1999) have shown 
that selected glycomimetics have the added potential 
to selectively target one of the fifteen human galectin 
family members. For instance compound 32 has a Kd 
of 32 nM against Galectin-3 (Van Hattum et al., 2013) 
The first demonstration that glycodendrimers could ef-
fectively show some level of selectivity has been shown 
with PAMAM-based lactose dendrimers illustrated in the 
red inset of Figure 5 (André et al., 1999). For instance, 
the lactose-PAMAM dendrimer in Figure 5 showed four 
fold enhancement of selectivity between Galectin-3 over 
Galectin-1. These results clearly illustrate the potential of 
using synthetic glycodendrimers as antimetastatic agents.
Gold glyconanoparticles as vaccines
Gold nanoparticles (NPs) are the most stable and 
studied among the metal based nano-clusters. Even 
though, a large number of methodologies are known for 
the preparation of gold NPs, the Burst technique or its 
variation are still the most popular for preparing mono-
layer of coated gold NPs, which is based on the high af-
finity of the thiol groups towards the gold atoms because 
of the soft character of both Au and S atoms (Brust et al., 
1994). In this method, gold NPs are synthesized through 
reduction of gold salt (HAuCl4) by NaBH4 in the presence 
of a thiol. Gold NPs coated with glycan monolayers have 
been studied extensively in various areas of biomedical 
research (Marradi, Martín-Lomas, Penadés, 2010; Mar-
radi et al., 2010; Chang-Ming, 2011; Reichardt, Martín-
Lomas, Penadés, 2013). Since the first report in 2001 (De 
La Fuente et al., 2001), gold glyconanoparticles (GNPs) 
received great attention among glycochemists.
Gold NPs have been used as multivalent and mul-
tifunctional platforms for tumor associated carbohydrate 
antigens in combination with suitable immunogenic carri-
ers to develop carbohydrate based vaccines. The pioneer-
ing group of Penadés has been the first to identify gold 
NPs as potential scaffolds for vaccine preparation (De La 
Fuente et al., 2001). Accordingly, in an early report, hybrid 
glycoNPs have been synthesized by combining the LewisY 
(25) and the TF (26) oligosaccharides tumor markers, a 
peptide from tetanus toxoid (TT) as T-cell helper (27) 
FIGURE 10 - Multicomponent TACA vaccine incorporating of the requisite elements to raise both humoral and cytotoxic immunity 
(Galan, Dumy, Renaudet, 2013).
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FIGURE 11 – Synthetic monovalent glycomimetics acting as selective galectin inhibitors.
and inert interspacing glucose moieties (28) to control the 
density of the above conjugates (Figure 12). Preliminary 
data showed that this hybrid glycoGNPs exhibited potent 
immunogenic activity.
In a more recent investigation, Barchi Jr. and 
co-workers reported another potential tumor vaccine 
construction prepared from QDs (Svarovsky, Barchi 
Jr., 2007) and gold NPs (Svarovsky, Szekely, Barchi Jr. 
FIGURE 12 - Molecular structures of gold NPs based tumor vaccines exposing various sugar epitopes.
2005; Sundgren, Barchi Jr., 2008; Brinãs et al., 2012). 
Analogous gold glycoNPs have been loaded with three 
components that included: i) glycopeptides from Mucin-4, 
the Thomsen- Friedenreich antigen (TF-26) at various 
positions, ii) 28-residue peptide from complement derived 
protein C3d as a B-cell activating molecular adjuvant. In 
in vivo studies, sera from mice immunized with this gly-
coNPs, showed small but statistically significant antibody 
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responses (both IgG and IgM) against the carbohydrate 
antigen. In addition to TF-functionalized glycoNPs, gly-
coconstructs from the peptides without the TF-antigen or 
linker alone also showed some immunogenicity. Among 
the TF functionalized glycoNPs, the mono functionalized 
conjugates showed the highest activity. The respective 
positioning of the TF-antigen along the peptide chain 
showed better selectivity toward IgG over IgM, whereas 
conjugates with the sugar at other positions exhibited 
similar selectivity for both IgG and IgM. Even though the 
results are still preliminary, the efficiency of glyco-NPs to 
acts as scaffolds for vaccine construction was successfully 
shown in both of the above applications.
GLYCODENDRIMERS AS BACTERIAL ANTI-
ADHESINS
Infection by pathogens is generally initiated by 
crucial steps of recognition and adhesion on host epithelia 
surfaces. Very frequently, the strategy used by micro-
organisms involves the binding to host glycoconjugates by 
sugar-binding proteins, lectins, which are specific for the 
target tissue. The dependence between pathogen receptors 
and host glycans leads to the concept of “glycoecology” 
(Roy, 2003; Imberty, Chabre, Roy, 2008). In turn, the host 
immune system can also use lectins to identify and bind 
oligo- and polysaccharides on micro-organism surface, 
but in some cases the pathogens can reroute this process 
and use it for invasion. These infection strategies involve 
interactions characterized by their high specificity and 
most of the time by multivalency. The biochemical and 
structural data that have been accumulated recently offer 
chemists the possibility to interfere in the infection process 
through molecules that mimic the natural oligosaccharidic 
ligands and effectively compete for attachment sites. Dif-
ferent strategies using modified oligosaccharides, glyco-
mimetics, oligomers, dendrimers, or polymers have been 
developed to enhance the overall affinity of carbohydrate 
ligands (Roy, 2003; Imberty, Chabre, Roy, 2008; Bernardi 
et al., 2013; Branson, Turnbull, 2013; Jiménez Blanco, 
Mellet, García Fernández, 2013).
Uropathogenic Escherichia coli infections, ultimately 
leading to cystitis and pyelonephritis, are initially mediated 
by the adhesion of the bacterial FimH to the transmembrane 
glycoprotein uroplakin-1a present at the surface of urothe-
lial cells (Figure 13). The adhesion is based on the recogni-
tion and high avidity binding between the high-mannose 
glycans of the uroplakin and the FimH, a mannose-specific 
lectin located at the tip of type 1 fimbriae. It was found 
that synthetic multiantennary mannopyranosides glyco-
dendrons, harboring triazole functionality at the anomeric 
position, were potent hemagglutination inhibitors of guinea 
pig erythrocytes and E. coli. A mannosylated dendrimer 
exposing up to sixteen sugar residues showed an HAI 
titer of 1 μM and was thus 500-fold more potent than the 
corresponding monovalent methyl α-D-mannopyranoside 
(Figure 14). The synthesis of the glycodendrons involved 
highly efficient solid-phase synthesis of branched L-lysine 
scaffolds, diazo transfer reaction on the terminal amine 
residues, and [1,-3]-dipolar copper-catalyzed azide-alkyne 
FIGURE 13 - Glycodendrimer inhibition strategy to block bacterial adhesion to host tissues. Given the usual low affinity of 
monovalent carbohydrate ligands toward bacterial lectins, multivalent ligand presentation on dendritic scaffolds leads to more 
potent candidates.
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FIGURE 14 – Selected family members of glycodendrimers used against bacterial infections. Although they all harbour α-D-
mannopyrannoside ligands against uropathogenic E. coli FimH; analogous scaffolds were used with different saccharides moities 
recognized by other bacterial lectins.
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cycloaddition using propargyl α-D-mannopyranoside (Pa-
padopoulos, Shiao, Roy, 2012).
Several different classes of glycodendrimers harbor-
ing α-D-mannopyranoside residues have been synthesized 
in the past from our groups (Figure 14) (Touaibia, Roy, 
2007; Chabre, Roy, 2008) and from others (Röckendorf, 
Lindhorst, 2001; Hartmann, Lindhorst, 2011), includ-
ing calyx[4]arenes (Sansone, Casnati, 2013), fullerene 
(Chabre, Roy, 2013), and cyclodextrins (Martínez, Mel-
let, Garcia Fernández, 2013). Figure 14 illustrates typical 
cases wherein L-lysine (Nagahori et al., 2002) was used as 
scaffold (33, 37, 38), together with “Majoral-type” cyclo-
triphosphazene (34) (Touaibia, Roy, 2008), and aromatic 
scaffolds that included hexaphenylbenzene (35) (Chabre 
et al., 2011) and hexamethylthiobenzene (36) (Chabre et 
al., 2008).
The syntheses of two different families of mannosyl-
ated dendrons were efficiently accomplished using solid 
phase chemistry. Of particular interest was the observation 
that both the diazo transfer reaction and the [1,3]-dipolar 
copper-catalyzed cycloaddition could be accomplished 
during the solid-phase steps. The 15 step syntheses of the 
G(3) dendrons (37) were accomplished in an average of 
16% overall yield. The second and extended family of 
mannodendrons (38), bearing an extra 6-aminohexanoic 
acid linker, showed better inhibitory potencies in inhibition 
of hemagglutination assays of guinea pig erythrocytes and 
fimbriated E. coli. The best candidate 38, with an HAI titer 
of 1 μM, showed a 32-fold better binding affinity when 
corrected on a per mannoside residue. This value compares 
favorably well with the ones recently published using 
fullerene (Durka et al., 2011) or pentaerythritol (Gouin 
et al., 2009) scaffolds. However, a linear heptameric 
mannocluster built on sugar scaffolds and having a more 
hydrophobic heptyl aglycon showed better HAI titers than 
the one reported herein (Almant et al., 2011). 
We also demonstrated (unpublished data) that some 
of the above mannosylated glycodendrimers were capable 
of inhibiting the binding of fluorescently-labelled plant 
lectin such as ConA from Canavalia ensiformis to brain 
cancer line U87 in a dose dependent manner (Figure 15). 
While monosaccharide methyl α-D-mannopyrannoside 
was unable to inhibit ConA from binding to U87, glyco-
dendrimer 37 could almost completely abolish the lectin 
from binding.
GOLD AND UPCONVERTING LANTHANIDE 
NANOPARTICLES
A novel and simple approach on which nanometer-
size (< 2 nm), water soluble glycodendrimer coated gold 
nanoparticles (Au-man) were reported that allowed the 
detection of protein-carbohydrate interactions based 
on surface energy transfer process (SET) (Figure 16) 
TABLE II - Relative inhibitory properties of the two series of mannosylated glycodendrimers measured by the hemagglutination 
titer (HAI) against guinea pig erythrocytes and fimbriated uropathogenic E. coli BW25113
Compound Nb surface groups (Valency) HAI titer (µM) Relative potency
Relative potency/
Mannoside
Me αD-Man 1 500 1 1
G(0)a 2 78.1 6 3
G(1)a 4 62.5 8 2
G(2)a 8 15.6 32 4
37 G(3) 16 2.0 256 16
G(1)b 4 62.5 8 2
G(2)b 8 7.8 64 8
38 G(3) 16 1.0 512 32
a Structures without spacer in the α-Lys position (not shown). b Structures with spacer in the α-Lys position (not shown).
FIGURE 15 – Inhibition of binding of fluorecently-labelled 
plant lectin ConA to glyoblastomas U87 by mannodendrimer 37.
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(Bodgan, Roy, Morin, 2012). The Gold-NPs were con-
structed from poly(amidoamine) PAMAM generation G0 
dendrimers scaffolded on cystamine using the borohydride 
reduction of a gold salt (Brust et al., 1994).
The amine-exposed Gold-NPs were then treated 
with p-isothiocyanatophenyl α-D-mannopyranoside. This 
sensitive SET sensing approach enables quantitative anal-
ysis of the binding constant of a mannose-binding protein, 
lectin Concanavalin A (Con A) labelled with a fluorophore 
to a sensing Au-Mannoside in aqueous samples. Competi-
tive binding and inhibition assays were done to investigate 
the SET efficiency. The binding constant of Con A to 
Au–Man interactions of (5.6 ± 0.1) x 106 M-1 was shown 
to be 100-times higher than the binding constant values 
obtained in the interactions with the glycodendrimer G2 
alone. The simple modification of the gold nanoparticles 
with glycodendrimers provided a convenient method to 
obtain biocompatible and selective carbohydrate-based 
SET probes for protein biorecognition.
It was also demonstrated that the efficiency of SET 
decreases when mannan, a mannose polysaccharide, 
blocked efficiently the receptors of lectin as only 10% of 
FIGURE 16 – Water-soluble Gold-NPs constructed with surrounding PAMAM dendrimers to which were linked thioureas ending 
with mannopyranoside derivative.
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fluorescence of FITC–Con A was decreased after addition 
of Au–Man. In addition, the efficiency of SET decreases 
in the presence of an inhibitor as the fluorescence of 
FITC–Con A in complex with Au–Man was recovered up 
to 80% after addition of the monomeric α-D-mannose used 
in molar concentration. For further application, this novel 
SET sensing glycodendrimer coated gold nanoparticles 
could be used in bacteria and cancer detection as well as 
in protein microarray assays.
Interestingly, these mannoside-bound Gold-NPs 
could be selectively precipitated with their cognate lectins 
while they did not agglutinate in the presence of other 
unrelated lectins such as wheat germ agglutinin (WGA). 
In addition, the precipitate could be recovered for protein 
purifications and the Gold pellets could be recovered 
with large concentration of D-mannose but not with D-
galactose by competive inhibition. More surprisingly, it 
was found that the mannose-NPs could provoke the clus-
tering of piliated E. coli, thus demonstrating their potential 
usefulness as biosensors.
Similarly, upconverting lanthanide (Ln3+)-doped 
nanoparticles conjugated with glycodendrimers capable 
of recognizing lectins based on luminescence resonance 
energy transfer (LRET) were also developed in our group 
(Bogdan et al., 2010). Poly(amidoamine) (PAMAM) 
dendrimers were adsorbed on the surface of NaGdF4:Er3+, 
Yb3+ upconverting nanoparticles (LnNPs) via direct 
ligand-exchange followed by efficient thiourea linkage 
formation between the amine surface and p-isothiocya-
natophenyl α-D-mannopyranoside for covalent carbohy-
drate derivatization. The resulting water dispersible and 
biocompatible mannose coated PAMAM-LnNPs of 25 nm 
size were used to recognize a lectin, Concanavalin A (a 
mannose binding protein) conjugated with tetramethylrho-
damine (RITC-Con A) via LRET from the upconverting 
mannose-coated PAMAM-LnNPs, which act as energy 
donors to the RITC-labeled lectin molecules serving as 
energy acceptors. The energy transfer phenomenon from 
the mannose-coated PAMAM-LnNPs, following 980 nm 
excitation, to the RITC-Con A was observed with increas-
ing emissions at 585 nm, as the concentration of lectin 
increases. These novel carbohydrate-coated LnNPs prove 
to be a novel tool to monitor the binding interaction with 
lectins in aqueous samples (Figure 17).
CONCLUSION
This review has unequivocally demonstrated that, 
when key carbohydrate residues are grafted onto nanopar-
ticles of varied genesis, they can successfully contribute 
to many advantages toward biomedical applications. The 
mixed expertise in nanosciences, glycochemistry and gly-
cobiology, coupled to expert knowledge in photophysics, 
has permitted to push the frontiers of nanomaterials closer 
to nanomedicine. Several examples have also been used to 
demonstrate that once glycosylated, several hitherto toxic 
nanoparticles can acquire cellular safety. The rapidly grow-
ing interest for this moving field is providing a wonderful 
tool box wherein scientists’ creativity will constitute the 
only limitation. Better insights into multivalent carbohy-
drate-protein interactions will further our appreciation of the 
“glycocodes” complexity which should undoubtedly allow 
more precisely the targeting of drugs and genes delivery.
If state of the art synthetic organic methodologies are 
combined to carbohydrate chemistry, it appears straightfor-
wardly that the next generation of glyconanoparticles will 
exemplify even more complex saccharide structures that 
will likely also include glycomimetics. This last statement 
FIGURE 17 – Upconverting lanthanide nanoparticles coated with α-D-mannopyranoside residues anchored to PAMAM dendrimers 
via thiourea linkages.
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simply follows the actual trends in improved carbohydrate 
ligands and inhibitors design that encompasses more hy-
drolytically stable analogues, most of which successfully 
demonstrating much simpler hybrid glyco-pharmacophore 
structures that better mimics newer drug conceptions.
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